GWPH News and Press, GW Pharmaceuticals Plc From 03/08/20

The severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 for short, has definitely made its presence felt on Wall Street during the opening weeks of 2020. Despite a strong start to 2020, the  Dow Jones Industrial Average , the  Nasdaq Composite , and the  S&P 5...

Shares of British drugmaker GW Pharmaceuticals (NASDAQ: GWPH) shed an eye-catching 11.4% of their value in February, according to data from  S&P Global Market Intelligence . The company took a big hit after reporting fourth-quarter and full-year results on Feb. 25, but earnings...

There's no denying that there's a lot of growth potential for the cannabis industry. Grand View Research expects that the global legal marijuana market will be worth $73.6 billion by 2027, up from an estimated $18 billion in 2019.  And while there are significant opportunities for cannabis...

Even researchers can’t keep up with the growth of the CBD market in the U.S. Cowen & Co. had projected this fast-moving market at $15 billion by 2025. Now a study by BDS Analytics and Arcview Research finds it will be $20+ billion by 2024. A key difference: the $20+ billion finding ...

In CBD, a rare combination of quality product, aggressive marketing and a willingness to expand product lines is vital to gain market share. CBD Unlimited, Inc. ( OTC PINK: EDXC ), a provider of phytonutrient-based food and nutritional products, met that criteria again when it announced on M...

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $69 (55% upside) price target at Citigroup. More news on: ACADIA Pharmaceuticals Inc., Alector, Inc., GW Pharmaceuticals plc, Healthcare stocks news, , Stocks on the move, Read more ...

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. While the idea of using LSD, MDMA, and psilocybin (the main hallucinogenic compound in magic mushrooms) to treat mental health disorders is far from...

The Q4 results of GW Pharma (NASDAQ: GWPH ) continue the strong progress the company has been making. This was a continuation of the picture from Q3. The figures did not come as a surprise as the company had provided provisional results in January, which I wrote about here. In my article ...

GW Pharmaceuticals (NASDAQ: GWPH) boasts the first plant-based cannabinoid pharmaceutical agent on the market with its treatment, Epidiolex. The Food and Drug Administration approved Epidiolex in June 2018 as a treatment for seizures associated with Dravet syndrome and Lennox-Gastaut syndrom...

February 27, 2020 Palm Beach, FL – February 27, 2020 — The European CBD market has big potential says a new survey from New Frontier Data .  In fact, they found that Europe has a growing consumer base that has very positive views on CBD.  Per feedback from 3...